Nouscom appoints new Chief Operating Officer and strengthens the Board of Directors with industry veterans and scientifics experts

Basel, Switzerland – 26 September 2016 Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced the [...]

NousCom presents at Agenda Sachs Forum

Full program: http://www.sachsforum.com/uploads/5/1/9/6/51964431/17thbef-finalagenda.pdf

NousCom presents at 3rd CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

Mainz, Germany Abstract Title: Great Apes Adenovirus neoantigens vaccine synergizes with immunomodulators in mouse models of cancer.